These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 29508087)

  • 1. Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention.
    Lee DH; Fradley MG
    Curr Treat Options Cardiovasc Med; 2018 Mar; 20(3):19. PubMed ID: 29508087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management.
    Patel VG; Cornell RF
    Curr Oncol Rep; 2019 Mar; 21(4):29. PubMed ID: 30834998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Agents in Multiple Myeloma: An Examination of Safety Profiles.
    Bringhen S; De Wit E; Dimopoulos MA
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):391-407.e5. PubMed ID: 28601492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontline therapy for newly diagnosed patients with multiple myeloma.
    Jung SH; Jo JC; Song GY; Ahn SY; Yang DH; Ahn JS; Kim HJ; Lee JJ
    Blood Res; 2020 Jul; 55(S1):S37-S42. PubMed ID: 32719175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment algorithms for multiple myeloma in Japan].
    Ozaki S
    Rinsho Ketsueki; 2017; 58(8):1014-1023. PubMed ID: 28883264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
    Berenson A; Vardanyan S; David M; Wang J; Harutyunyan NM; Gottlieb J; Halleluyan R; Spektor TM; Udd KA; Eshaghian S; Nassir Y; Eades B; Swift R; Berenson JR
    Ann Hematol; 2017 Mar; 96(3):449-459. PubMed ID: 27933373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies:
    Georgiopoulos G; Makris N; Laina A; Theodorakakou F; Briasoulis A; Trougakos IP; Dimopoulos MA; Kastritis E; Stamatelopoulos K
    JACC CardioOncol; 2023 Feb; 5(1):1-21. PubMed ID: 36875897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma.
    Cole DC; Frishman WH
    Cardiol Rev; 2018; 26(3):122-129. PubMed ID: 29077585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular adverse events in multiple myeloma patients.
    Heckmann MB; Doroudgar S; Katus HA; Lehmann LH
    J Thorac Dis; 2018 Dec; 10(Suppl 35):S4296-S4305. PubMed ID: 30701098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.
    Ntanasis-Stathopoulos I; Terpos E; Dimopoulos MA
    Cancer J; 2019; 25(1):2-10. PubMed ID: 30694854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
    Raza S; Safyan RA; Lentzsch S
    Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?
    Sonneveld P; De Wit E; Moreau P
    Crit Rev Oncol Hematol; 2017 Apr; 112():153-170. PubMed ID: 28325256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
    Zangari M; Fink L; Zhan F; Tricot G
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral Artery Disease and Stroke.
    Zito C; Manganaro R; Carerj S; Antonini-Canterin F; Benedetto F
    J Cardiovasc Echogr; 2020 Apr; 30(Suppl 1):S17-S25. PubMed ID: 32566462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG; Hideshima T; Mitsiades C; Anderson KC
    J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
    Vij R
    Oncology (Williston Park); 2011 Nov; 25 Suppl 2():45-55. PubMed ID: 25188481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.